A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
- Status
- COMPLETED
- Phase
- PHASE3
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
- Status
- COMPLETED
- Phase
- PHASE3
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
- Status
- UNKNOWN
- Phase
- PHASE2
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
- Status
- COMPLETED
- Phase
- PHASE2
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
- Status
- COMPLETED
- Phase
- PHASE2
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Phase I (PH I) Mad Refractory Solid Tumor Study
- Status
- COMPLETED
- Phase
- PHASE1
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
- Status
- COMPLETED
- Phase
- PHASE2